Heilbronn, Germany

Time filter

Source Type

Grant
Agency: Cordis | Branch: FP7 | Program: CP-FP | Phase: KBBE-2008-3-1-05 | Award Amount: 4.40M | Year: 2009

The CoMoFarm project will establish high-yielding production systems for pharmaceutical and industrial proteins based on plants, plant tissue and plant cells. The aim is to develop systems in which both the production host and the product itself show consistent yield and quality. The project will include a comparison of four alternative systems hydroponic plants, root cultures, moss and suspension cells, and will involve the evaluation of different species, strain and process optimization, scale-up, downstream processing, protein characterization and process evaluation in terms of regulatory compliance. As well as furthering the development of an emerging production technology, the project will incorporate numerous innovative elements such as in-process monitoring and automation of environmental parameters to maintain a consistent environment and optimize protein yield and homogeneity, novel downstream processing technologies and innovative bioreactor and hydroponic designs to maintain plant health and ensure production according to good manufacturing practice. This project will have an immense impact on the biopharmaceuticals industry, by allowing SMEs interested in molecular farming to develop plant-made pharmaceuticals without worrying about regulatory constraints or poor investment prospects. This will go a long way to establishing molecular farming as a feasible industry within Europe, and will open new revenue streams for companies currently not interested in (or aware of) molecular farming, e.g. horticulture companies and nurseries. The cost of drugs will also begin to fall, which will positively re-enforce the benefits of plants and lead to greater growth in the market.


News Article | February 22, 2017
Site: marketersmedia.com

— The report provides comprehensive information on the therapeutics under development for Gaucher Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Gaucher Disease and features dormant and discontinued projects. GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/543761-gaucher-disease-pipeline-review-h1-2016 Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Scope - The report provides a snapshot of the global therapeutic landscape of Gaucher Disease - The report reviews pipeline therapeutics for Gaucher Disease by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Gaucher Disease therapeutics and enlists all their major and minor projects - The report assesses Gaucher Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Gaucher Disease Reasons to buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Gaucher Disease - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Gaucher Disease pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Table of Content: Key Points Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Gaucher Disease Overview 9 Therapeutics Development 10 Pipeline Products for Gaucher Disease - Overview 10 Pipeline Products for Gaucher Disease - Comparative Analysis 11 Gaucher Disease - Therapeutics under Development by Companies 12 Gaucher Disease - Therapeutics under Investigation by Universities/Institutes 13 Gaucher Disease - Pipeline Products Glance 14 Clinical Stage Products 14 Early Stage Products 15 Gaucher Disease - Products under Development by Companies 16 Gaucher Disease - Products under Investigation by Universities/Institutes 17 Gaucher Disease - Companies Involved in Therapeutics Development 18 Actelion Ltd 18 Bioorganic Research and Services S.A. 19 Genzyme Corporation 20 greenovation Biotech GmbH 21 JCR Pharmaceuticals Co., Ltd. 22 Lixte Biotechnology Holdings, Inc. 23 Neuraltus Pharmaceuticals, Inc. 24 …Continued For more information, please visit http://www.wiseguyreports.com


Patent
greenovation Biotech | Date: 2013-04-17

The invention relates to a method for producing a recombinant protein in cells with a cell wall, comprising the step of increasing the secretion of the recombinant protein through the cell wall by expression of the protein in the cells in a culture medium containing a combination of a surface-active polymer and monovalent metal ions and with an osmolarity at least 0.32 osmol/L, said invention further relating to culture media and nutrient mixtures for the method.


Patent
greenovation Biotech | Date: 2015-05-28

The present invention relates to an antibody preparation comprising modified antibodies of an animal or derivatives or fragments thereof, specific for an antigen, characterized in that the antibodies or derivatives or fragments thereof comprise an N-glycan structure free of fucose and xylose, and at least 90%, preferably at least 95%, more preferred at least 99%, most preferred at least 100% of the modified antibodies, derivatives or fragments thereof lack a C-terminal lysine residue.


Patent
greenovation Biotech | Date: 2013-07-19

The invention relates to a method for separating off a liquid supernatant from cells, comprising the steps: providing a mixture of the cells with a liquid, charging a first filter housing with the mixture, wherein in the filter housing a filter having a pore size of between 4 m and 50 m is provided on a flat base surface pierced in a sieve manner and the walls of the filter housing are connected so as to seal with the flat base surface that is pierced in a sieve manner, applying a differential pressure of at least 0.5 bar on the mixture, as a result of which the liquid portion of the mixture is forced through the filter and a filter cake containing cells remains in the filter housing, and removal of the filtered liquid.


Patent
Meridian and greenovation Biotech | Date: 2010-03-29

The invention relates to an immunogenic antibody which comprises at least two different epitopes of a tumor-associated antigen.


The invention relates to a kit for the combined use for the treatment of cancer patients, which set comprises an antigen of a cellular surface protein, or an antibody directed against the cellular surface protein, and an antigen of an aberrant glycosylation, or an antibody directed against the aberrant glycosylation. This kit is destined both for the immunotherapeutic and the diagnostic application. The invention further relates to a selection method for selecting suitable tumor-specific antigens with the assistance of this kit and corresponding specific antibody preparations.


Patent
greenovation Biotech | Date: 2014-10-15

The invention relates to expressing a glycoprotein with a mammalian-type phosphoglycosylation in a plant comprising expressing said glycoprotein in a plant which has been recombinantly modified to express non-plant enzymes capable of modifying the post-translational pathway of the plant to allow the mammalian-type phosphoglycosylation. Recombinant enzymes may be from the group of N-acetylglucosamine-1-phosphotransferase (GNPT), N-acetylglucosamine-1-phosphodiester-alpha-N-acetylglucosaminidase (NAGPA), mannosyl-phosphate-transferase Mnn6p and optional further regulatory proteins.


Patent
Meridian and greenovation Biotech | Date: 2010-05-24

The invention relates to a monoclonal antibody or derivative or fragment thereof that is derived from a parental monoclonal antibody, that recognizes the Lewis Y antigen, characterized in that the Fc region or region equivalent to the Fc region of said antibody or derivative or fragment thereof carries a bi-sected hybrid type N-glycosylation pattern and that said antibody shows at least 10 fold increased ADCC and at least 10% reduced CDC activity.


Patent
greenovation Biotech | Date: 2011-09-28

The present invention relates to an antibody preparation comprising modified antibodies of an animal or derivatives or fragments thereof, specific for an antigen, characterized in that the antibodies or derivatives or fragments thereof comprise an N-glycan structure free of fucose and xylose, and at least 90%, preferably at least 95%, more preferred at least 99%, most preferred at least 100% of the modified antibodies, derivatives or fragments thereof lack a C-terminal lysine residue.

Loading greenovation Biotech collaborators
Loading greenovation Biotech collaborators